The European Medicines Agency (EMA) has been in the constant process of assessing the applications received from many pharma firms that had been developing the Covid vaccine. It’s well known that UK’s AstraZeneca Plc is a frontrunner in the race and reported some positive results after testing it on few individuals.
However, the details of later stages of clinical trials were not documented well as per the experts’ opinion. There were also speculations that the firm has applied to EU (European Union) and is awaiting the approval this week. It also assured that their vaccine would battle the new variant. But things seemed to have turned tipsy turvy!.
In this regard EMA has been tough to escalate the permits and it is now unlikely to give a green signal to AstraZeneca and Oxford University’s Covid-19 vaccine in January 2021. The EMA’s deputy executive director Noel Wathion stated that the pharmaceutical company “has not even filed an application” with the European drug regulators yet.
He further added that EMA “did not even have enough to warrant a conditional marketing license.” Generally it requires more in-depth data on the vaccine quality and safety. Subsequently the vaccine producers can formally apply for approval from EMA. Now with unprepared information, it looks “improbable” to get the permit as early as next month i.e in January.